Modeling Molecular Mechanisms of Pirfenidone Interaction with Kinases
Preprint
Abstract
Scar formation is a process that occurs due to increased collagen deposition and uncontrolled inflammation. Previous studies have demonstrated that Pirfenidone (Pf), an FDA approved anti-inflammatory and anti-fibrotic drug can reduce inflammation in vivo as well as regulate activation of LPS-stimulated neutrophils. However, the molecular level mechanism of Pf’s action is not well understood. Here, we used neural networks to identify new targets and molecular modeling methods to investigate the Pf’s action pathways at the molecular level that are related to its ability to reduce both the inflammatory and remodeling phases of the wound healing process. Out of all the potential targets identified, both molecular docking and molecular dynamics results suggest that Pf has a noteworthy binding preference towards the active conformation of the p38 mitogen activated protein kinase-14 (MAPK14) and it is potentially a type I inhibitor-like molecule. In addition to p38 MAPK (MAPK14), additional potential targets of Pf include AKT1, MAP3K4, MAP2K3, MAP2K6, MSK2, MAP2K2, ERK1, ERK2, and PDK1. We conclude that several proteins/kinases, rather than a single target, are involved in Pf’s wound healing ability to regulate signaling, inflammation, and proliferation.Keywords
This publication has 25 references indexed in Scilit:
- cando.py: Open Source Software for Predictive Bioanalytics of Large Scale Drug–Protein–Disease DataJournal of Chemical Information and Modeling, 2020
- CANDOCK: Chemical Atomic Network-Based Hierarchical Flexible Docking Algorithm Using Generalized Statistical PotentialsJournal of Chemical Information and Modeling, 2020
- Pirfenidone attenuates the profibrotic contractile phenotype of differentiated human dermal myofibroblastsBiochemical and Biophysical Research Communications, 2020
- Pirfenidone Ointment Modulates the Burn Wound Bed in C57BL/6 Mice by Suppressing Inflammatory ResponsesInflammation, 2018
- Treating Heart Failure with Preserved Ejection Fraction: Learning from Pulmonary FibrosisEuropean Journal of Heart Failure, 2018
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexesPharmacological Research, 2016
- Current Compound Coverage of the KinomeJournal of Medicinal Chemistry, 2014
- CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fieldsJournal of Computational Chemistry, 2009
- Scleroderma: from cell and molecular mechanisms to disease modelsTrends in Immunology, 2005
- GROMACS: Fast, flexible, and freeJournal of Computational Chemistry, 2005